nabiximols
nabiximols: sourced relationships with 1 company · 2 clinical trials tracked.
nabiximols evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could nabiximols → GWPH affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence3 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| GW PHARMACEUTICALS PLC (GWPH) Spasticity due to multiple sclerosis | Phase 3 |
Clinical Trial Registry Records (2)
A Phase IIb Study of the Safety and Efficacy of Nabiximols in Subjects With Spasticity Due to Neuromyelitis Optica Spectrum Disorders: A Double-blind, Randomized, Placebo-Controlled, Crossover Study
Primary endpoint: Change in mean Numeric Rating Scale - Spasticity (NRS-S) scores from pre-treatment to post-treatment
A Randomised Controlled Phase II Trial of Temozolomide With or Without Cannabinoids in Patients With Recurrent Glioblastoma
Primary endpoint: Overall survival time (OS)
Frequently asked questions
Which companies have sourced relationships with nabiximols?
nabiximols has dated SEC/FDA relationship records for GW PHARMACEUTICALS PLC.
How many clinical trials involve nabiximols?
BioSniper tracks 2 clinical trials involving nabiximols.